Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 32, 2009, Pages 13433-13438

  Chen, Shih Shih ^a,b   Raval, Aparna ^a,c   Johnson, Amy J ^b   Hertlein, Erin ^b   Liua, Te Hui ^a,d   Jin, Victor X ^a   Sherman, Mara H ^e   Liu, Shu Jun ^b   Dawson, David W ^d   Williams, Katie E ^b   Lanasa, Mark ^f   Liyanarachchi, Sandya ^a   Lin, Thomas S ^b   Marcucci, Guido ^a,b   Pekarsky, Yuri ^a   Davuluri, Ramana ^a   Croce, Carlo M ^a   Guttridge, Denis C ^a   Teitell, Michael A ^e   Byrd, John C ^a,b   Plass, Christoph ^a,g   more..

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CLL; DNA methylation; Epigenetics; FOXD3

Indexed keywords

HISTONE DEACETYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXD3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BINDING SITE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; NF-KAPPA B P50 SUBUNIT; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TRANS-ACTIVATORS;

ANIMALIA; MURINAE; MUS; MUS MUSCULUS;

EID: 69449100327     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0906455106     Document Type: Article

References (44)

1. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692.
2. Weber M, et al. (2005) Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37:853-862. (Pubitemid 41077111)
3. Suganuma T, Workman JL (2008) Crosstalkamonghistone modifications. Cell 135:604-607.
4. Preuss SB, et al. (2008) Multimegabase silencing in nucleolar dominance involves siRNA-directed DNA methylation and specific methylcytosine-binding proteins. Mol Cell 32:673-684.
5. Schones DE, Zhao K (2008) Genome-wide approaches to studying chromatin modifications. Nat Rev Genet 9:179-191.
6. Costello JF, et al. (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138.
7. Bachman KE, et al. (2003) Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3:89-95. (Pubitemid 37443893)
8. Chan TL, et al. (2006) Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 38:1178-1183. (Pubitemid 44470364)
9. Gaudet F, et al. (2003) Induction of tumors in mice by genomic hypomethylation. Science 300:489-492. (Pubitemid 36444330)
10. Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer - A mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107-116.
11. Bichi R, et al. (2002) Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 99:6955-6960. (Pubitemid 34526239)
12. Johnson AJ, et al. (2006) Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 108:1334-1338.
13. Browning RL, et al. (2007) Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk Res 31:1737-1740.
14. Costello JF, Plass C, Cavenee WK (2002) Restriction landmark genome scanning. Methods Mol Biol 200:53-70.
15. Rush LJ, et al. (2004) Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 64:2424-2433.
16. Ehrich M, et al. (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 102:15785-15790. (Pubitemid 41552820)
17. Yu L, et al. (2005) Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 37:265-274. (Pubitemid 41716253)
18. Opavsky R, et al. (2007) CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS Genet 3:1757-1769. (Pubitemid 47510267)
19. Brenner C, et al. (2005) Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J 24:336-346. (Pubitemid 40216138)
20. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428.
21. Leu YW, et al. (2004) Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 64:8184-8192.
22. Kel AE, et al. (2003) MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 31:3576-3579. (Pubitemid 37442201)
23. Zhong H, May MJ, Jimi E, Ghosh S (2002) The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9:625-636. (Pubitemid 34273792)
24. Dong J, Jimi E, Zhong H, Hayden MS, Ghosh S (2008) Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms. Genes Dev 22:1159-1173. (Pubitemid 351656576)
25. Grundstrom S, Anderson P, Scheipers P, Sundstedt A (2004) Bcl-3 and NFkappaB p50-p50 homodimers act as transcriptional repressors in tolerant CD4+ T cells. J Biol Chem 279:8460-8468. (Pubitemid 38294739)
26. Pekarsky Y, et al. (2000) Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 97:3028-3033. (Pubitemid 30183249)
27. Tompers DM, Foreman RK, Wang Q, Kumanova M, Labosky PA (2005) Foxd3 is required in the trophoblast progenitor cell lineage of the mouse embryo. Dev Biol 285:126-137. (Pubitemid 41242820)
28. Sutton J, et al. (1996) Genesis, awinged helix transcriptional repressor with expression restricted to embryonic stem cells. J Biol Chem 271:23126-23133. (Pubitemid 26314748)
29. Pan G, Li J, Zhou Y, Zheng H, Pei D (2006) A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal. FASEB J 20:1730-1732.
30. Guo Y, et al. (2002) The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression. Proc Natl Acad Sci USA 99:3663-3667. (Pubitemid 34252163)
31. Williams SA, et al. (2006) NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 25:139-149.
32. Oakley F, et al. (2005) Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury. Am J Pathol 166:695-708. (Pubitemid 40315627)
33. Pekarsky Y, et al. (2008) Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 105:19643-19648.
34. Hewamana S, et al. (2008) The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111:4681-4689.
35. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ (2000) Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164:2200-2206. (Pubitemid 30108780)
36. Tada Y, et al. (2006) Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 98:396-406.
37. Chen CH, et al. (2005) Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO J 24:294-304.
38. Cohen J (1983) in Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences (Lawrence Erlbum Associates Inc., Hillsdale, NJ), 2nd Ed.
39. HollanderM(1999) in Nonparametric Statistical Methods (John Wiley & Sons Inc., NY), 2nd Edition.
40. Huttenhofer A, Brosius J, Bachellerie JP (2002) RNomics: Identification and function of small, non-messenger RNAs. Curr Opin Chem Biol 6:835-843. (Pubitemid 35449345)
41. Wingender E, et al. (2000) TRANSFAC: An integrated system for gene expression regulation. Nucleic Acids Res 28:316-319. (Pubitemid 30047792)
42. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties, and weight matrix choice. Nucleic Acids Res 22:4673-4680.
43. Jin VX, Rabinovich A, Squazzo SL, Green R, Farnham PJ (2006) A computational genomics approach to identify cis-regulatory modules from chromatin immunoprecipitation microarray data-a case study using E2F1. Genome Res 16:1585-1595. (Pubitemid 44878497)
44. Said JW, et al. (2001) TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab Invest 81:555-564.